Jacob P. Laubach
Expertise in
15
conditions

Dr. Jacob P. Laubach

Oncology | Hematology
450 Brookline Avenue, 
Boston, MA 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
15
conditions
450 Brookline Avenue, 
Boston, MA 

Overview

Jacob Laubach is an Oncologist and a Hematologist practicing medicine in Boston, Massachusetts.

Dr. Laubach is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Smoldering Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Transplant, and Bone Marrow Aspiration.

Dr. Laubach is board certified in Hematology, Internal Medicine, and Medical Oncology. He is actively involved in clinical research, co-authoring 177 peer reviewed articles and participating in 10 clinical trials. Dr. Laubach is currently accepting new patients.

Specialties

Oncology
Hematology

Licenses

Internal Medicine in NC

Board Certifications

Hematology
Internal Medicine
Medical Oncology

Fellowships

Duke University Medical Center-GME, 2008

Hospital Affiliations

Hartford Hospital
Massachusetts General Hospital
Brigham And Women's Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Community Health Options
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Dana-Farber Cancer Institute, Lipper Multiple Myeloma Center
450 Brookline Avenue, Boston, MA 02115

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Phase 1, Multicenter, Open-label, Dose-escalation Study of Sotatercept (ACE-011) in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
Phase 1, Multicenter, Open-label, Dose-escalation Study of Sotatercept (ACE-011) in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: June 25, 2026
Intervention Type: Drug
Study Drugs: ACE-011, Lenalidomide, Dexamethasone, Pomalidomide
Study Phase: Phase 1
Phase 2, Multi-Center, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of the Combination Regimen Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
Phase 2, Multi-Center, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of the Combination Regimen Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: April 30, 2026
Intervention Type: Drug
Study Drugs: Isatuximab, Lenalidomide, Bortezomib Injection, Dexamethasone
Study Phase: Phase 2
A Phase II Study of Elotuzumab in Combination With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
A Phase II Study of Elotuzumab in Combination With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: January 22, 2026
Intervention Type: Drug
Study Drugs: Elotuzumab, Pomalidomide, Bortezomib, Dexamethasone
Study Phase: Phase 2
A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma
A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma
Enrollment Status: Completed
Publish Date: January 13, 2026
Intervention Type: Drug, Procedure
Study Drugs: Bortezomib, Lenalidomide, Dexamethasone
Study Phase: Phase 2
A Phase I Study of Ibrutinib (PCI-32765) in Combination With Revlimid/Dexamethasone (Rd) in Relapsed/Refractory Multiple Myeloma
A Phase I Study of Ibrutinib (PCI-32765) in Combination With Revlimid/Dexamethasone (Rd) in Relapsed/Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: January 06, 2026
Intervention Type: Drug
Study Drugs: Ibrutinib, Lenalidomide, Dexamethasone
Study Phase: Phase 1
A Multicenter, Randomized, Open-label Phase 2 Study Evaluating the Safety and Efficacy of Three Different Regimens of Oral Panobinostat in Combination With Subcutaneous Bortezomib and Oral Dexamethasone in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma Who Have Been Previously Exposed to Immunomodulatory Agents
A Multicenter, Randomized, Open-label Phase 2 Study Evaluating the Safety and Efficacy of Three Different Regimens of Oral Panobinostat in Combination With Subcutaneous Bortezomib and Oral Dexamethasone in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma Who Have Been Previously Exposed to Immunomodulatory Agents
Enrollment Status: Completed
Publish Date: July 12, 2024
Intervention Type: Drug
Study Drugs: Panobinostat Capsules, Bortezomib Injection, Dexamethasone Tablets
Study Phase: Phase 2
A Phase I Open Label Study Of Panobinostat In Combination With Lenalidomide, Bortezomib, And Dexamethasone In Patients With Relapsed And Relapsed/Refractory Multiple Myeloma
A Phase I Open Label Study Of Panobinostat In Combination With Lenalidomide, Bortezomib, And Dexamethasone In Patients With Relapsed And Relapsed/Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: September 05, 2021
Intervention Type: Drug
Study Drugs: Panobinostat, Dexamethasone, Lenalidomide, Bortezomib
Study Phase: Phase 1
A Randomized Multicenter Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma
A Randomized Multicenter Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: November 21, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma
An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma
Enrollment Status: Withdrawn
Publish Date: August 14, 2018
Intervention Type: Drug
Study Phase: Phase 2
Genomic and Psychosocial Effects of the Relaxation Response Resiliency Program (3RP) on Patients With MGUS and Smoldering Multiple Myeloma
Genomic and Psychosocial Effects of the Relaxation Response Resiliency Program (3RP) on Patients With MGUS and Smoldering Multiple Myeloma
Enrollment Status: Completed
Publish Date: March 16, 2017
Intervention Type: Behavioral
Study Phase: Not Applicable
View 9 Less Clinical Trials

177 Total Publications

Macrophage reprogramming, not CD8 T cell dynamics, characterizes durable disease control following PD-1 blockade in smoldering myeloma.
Macrophage reprogramming, not CD8 T cell dynamics, characterizes durable disease control following PD-1 blockade in smoldering myeloma.
Journal: Leukemia
Published: May 09, 2026
Similar Doctors
Expertise in
19
conditions
Dr. Steven G. Dubois
Hematology | Oncology
Expertise in
19
conditions
Dr. Steven G. Dubois
Hematology | Oncology
Referral may be required

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 (0.1 miles away)
877-442-3324
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Steven Dubois is a Hematologist and an Oncologist practicing medicine in Boston, Massachusetts. Dr. Dubois is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Ewing Sarcoma, Embryonal Tumor with Multilayered Rosettes, Neuroblastoma, and Osteosarcoma. Dr. Dubois is currently accepting new patients.

Expertise in
24
conditions
Dr. Matthew M. Heeney
Hematology | Oncology
Expertise in
24
conditions
Dr. Matthew M. Heeney
Hematology | Oncology
Referral may be required

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 (0.1 miles away)
877-442-3324
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Matthew Heeney is a Hematologist and an Oncologist practicing medicine in Boston, Massachusetts. Dr. Heeney is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Sickle Cell Disease, Congenital Hemolytic Anemia, Hemolytic Anemia, Hemoglobinopathy, and Splenectomy. Dr. Heeney is currently accepting new patients.

Expertise in
23
conditions
Dr. Katherine A. Janeway
Hematology | Oncology
Expertise in
23
conditions
Dr. Katherine A. Janeway
Hematology | Oncology
Referral may be required

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 (0.1 miles away)
877-442-3324
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Katherine Janeway is a Hematologist and an Oncologist practicing medicine in Boston, Massachusetts. Dr. Janeway is highly rated in 23 conditions, according to our data. Her clinical expertise encompasses Osteosarcoma, Ewing Sarcoma, Adult Soft Tissue Sarcoma, Neuroepithelioma, and Bone Marrow Aspiration. Dr. Janeway is currently accepting new patients.

Frequently Asked Questions about Dr. Jacob P. Laubach

How do I make an appointment with Dr. Jacob P. Laubach?

You can book an appointment with Dr. Jacob P. Laubach by calling their office at 617-632-4218. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jacob P. Laubach a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jacob P. Laubach is classified as an Elite expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jacob P. Laubach specialize in?

While Dr. Jacob P. Laubach is a Oncology, they have specific expertise in Multiple Myeloma, Smoldering Multiple Myeloma, and Relapsed Refractory Multiple Myeloma (RRMM). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Jacob P. Laubach participate in research or clinical trials?

Yes. Dr. Jacob P. Laubach has published 177 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Dr. Jacob P. Laubach's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jacob P. Laubach accept my insurance?

Dr. Jacob P. Laubach accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 617-632-4218 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Laubach's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 24 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile